A team of medicinal chemists and pharmacists selected a collection of 1280 off-patent drugs with high chemical and pharmacological diversity, as well as known bioavailability and safety in humans.
|A unique collection of 1280 off-patent small molecules, 95% approved drugs (FDA, EMA and other agencies)|
|High chemical and pharmacological diversity|
|Specially designed to increase potential “high-quality” hits|
|Over the past 19 years, “hit-likeness” and “hit-workability” have been reported by users in|
|A constant quality control ensures high purity and stable compounds|
|In DMSO at 10 mM (from 100 µL up to 1 mL) or powder with cherry-picking option|
|PCL Premium||PCL Full Premium|
|Formulation||1280 molecules||1280 molecules|
|Format||10 mM in DMSO||10 mM in DMSO|
|Stability||5 years at -20°C||5 years at -20°C|
|Quantity||100 µL / compound||100 µL / compound|
|Database||Virtual file and USB key
(Excel®, sdf, rdf, db, pdf)
|Virtual file and USB key
(Excel®, sdf, rdf, db, pdf
|Plate and plate map customization||96 well plates (Greiner)|
|Hit Re-supply||Not included||FREE: up to 20 compounds|
|Hit follow-up||Not included||FREE Med Chem assistance|
|Always provided with a highly annotated database as structural data file (SDF), IsisBase (DB) as well as an XLS file. Annotation includes target, therapeutic class/effect, side effects, patent and AMDET information|
|Re-supply of any hit-compound up to 100 mg|
|High-throughput screening (HTS), high-content screening (HCS)|
|Drug repurposing / Orphan drug|
at International Meetings
The Prestwick Chemical Library® (PCL) is Prestwick’s flagship product dedicated to screening. It is a collection of 1280 molecules comprising 100% approved drugs (FDA, EMEA and other agencies) selected for their high chemical and pharmacological diversity. These off-patent drugs have known bioavailability and safety data in humans are available. The PCL was designed to reduce the risk of "low quality" hits and therefor the cost of the initial screening, and appears to be an efficient smart library for hit discovery.
The ensuing project was designed to optimize the benefits of the PCL1 through pharmacophore modelling. The pharmacophore characterization of the library was obtained by applying a multi-step approach, first starting with a clustering analysis based RDF pharmacophore similarity. The 1280 compounds of the PCL were found to be clustered in 385 groups: 217 clusters and 168 singletons were obtained. The aim of this work was to generate a model for each cluster and subsequently use these models for extending the PCL and have a pharmacophoric representation of the library. After evaluation on the Zinc 2 database, a random selection of pharmacophore models underwent an external validation process by using DrugBank3 and ChEMBL4 databases.
PD’s high prevalence (~1 million patients in the US), severe consequencesto the patients’ quality of life and high cost (est. $25 billion pa cost in the US). Both thesereasons make the search for a cure imperative. Traditional target based approaches havenot yet been fruitful. In an alternative approach, we chose to follow a repurposing approachand screen a library of previously safety approved drug compounds for neuroprotectiveactivity against PD using a Drosophila model of the disease.